Search

Displaying results 3321 - 3330 of 10000 in total
  1. Drug

    Ixekizumab

    go.drugbank.com/drugs/DB11569
    ApprovedInvestigational

    Ixekizumab is produced by recombinant DNA technology in a recombinant mammalian cell line and purified using standard technology for bioprocessing.

  2. Indication

    No primary neurological disease, idiopathic decreased mental activity

    go.drugbank.com/conditions/DBCOND0141360
    Drugs: Dihydro-alpha-ergocryptine · Dihydroergocornine · Dihydroergocristine · Epicriptine
    Synonyms: No primary neurological disease, idiopathic decreased mental activity, No primary neurologial disease, idiopathic decreased mental activity
  3. Drug

    Procaine benzylpenicillin

    go.drugbank.com/drugs/DB09320
    ApprovedVet approved

    Procaine benzylpenicillin is administered by deep intramuscular injection. It is slowly absorbed and hydrolyzed to benzylpenicillin. … This drug is used where prolonged exposure to benzylpenicillin at a low concentration is required.

  4. Drug

    Celiprolol

    go.drugbank.com/drugs/DB04846
    ApprovedInvestigationalWithdrawn

    Celiprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome.

    Synonyms: RS)-N'-{3-acetyl-4-[3-(tert-butylamino)-2-hydroxypropoxy]phenyl}-N,N-diethylurea
  5. Drug

    E59

    go.drugbank.com/drugs/DB18372
    Experimental

    E59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.

  6. Drug

    Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

    go.drugbank.com/drugs/DB15682
    ApprovedInvestigational

  7. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals.

  8. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

  9. Drug

    Bavituximab

    go.drugbank.com/drugs/DB05136
    Investigational

    It binds to phosphatidylserine and other exposed host cell lipids when induced by cellular stress. Additional analogs in the class include 3G4, 2aG4, 9d2 and Hu3g4.

  10. Drug

    Lurasidone

    go.drugbank.com/drugs/DB08815
    ApprovedInvestigational

    Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.